Power Of Rare Disease Patient Registries Touted By US FDA, Patients
Executive Summary
Patients describe how they connect with each other and advance research through registries; agency says it has accepted registry data as real-world evidence of a product's benefit.
You may also be interested in...
Biden To Give Away 10% Of US COVID-19 Vaccine Supply As He Mulls Call For Patent Waiver
President Biden announced plans to increase vaccination in the US as members of Congress and industry press the administration to take steps to expand global access to COVID-19 vaccines. BIO proposes an alternative to the TRIPS waiver that would expedite export of raw materials and manufacturing supplies.
US FDA Takes Star Turn In Recent Drug Ingredient Liability Lawsuits
Agency’s direct involvement in pharma product liability litigation is one of the most striking developments in the field over the past year; 16 cases in multidistrict litigation listed in chart showing status of settlements and upcoming bellwether trials.
FDA Panel Okays Keytruda’s Hepatocellular Carcinoma Indication, But Splits On Opdivo
In 5-4 vote, US FDA advisory committee recommends withdrawal of Opdivo’s accelerated approval for second-line treatment of HCC while unanimously supporting the indication in Keytruda pending outcome of ongoing studies.